搜索
>产品 > ADC药物靶点蛋白

ADC药物靶点蛋白

背景
ADC(Antibody Drug Conjugate)是将单克隆抗体通过偶联臂与小分子药物共价偶联形成的复合物,简言之,ADC药物就是将具有高度靶向性的抗体药与杀伤力强大的化疗药结合到一起,在肿瘤细胞内精准投放药物的同时避免化疗药对正常细胞的杀伤,因此,研究热度与日俱增。目前已有9款上市药物。ADC药物的构思最早是由德国诺贝尔奖得主Paul Ehrlich在20世纪初提出的。第一个ADC药物Mylotarg在2000年批准上市,一直到2019年ADC迎来爆发,2019年至今已经批准了5款ADC药物。根据EvaluatePharma和BCG预测,全球ADC药物研发市场预计在2024年将达到129亿美元。目前ADC药物研发的热点已经从血液瘤转移到实体瘤,寻找合适的药物靶点已经成为ADC研发企业争夺的热点。

ADC上市药物详情列表



ACROBiosystems已针对多种热门靶点开发了不同种属、不同标签的产品,适用于免疫、抗体筛选、SPR、细胞活性检测等实验。ACROBiosystems致力于协助您的药物开发,并将研发人员实际的实验操作和参数整理成了相应的protocol免费提供,可以帮助您节省研发周期,后续更有过表达细胞株及Kit产品上线,敬请关注哦~
产品列表

点击分子即可查看您感兴趣的产品详情哦

ACROBiosystems正在积极开发更多高质量ADC药物靶点分子。如果您有任何建议或定制要求,请随时与我们联系。联系我们

产品特点
高纯度—MALS 验证

图1.The purity of Human Her2, His Tag (Cat. No. HE2-H5225) was more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.

图2.The purity of Human EGF R, His Tag(Cat. No. EGR-H5222) was more than 90% and the molecular weight of this protein is around 90-115 kDa verified by SEC-MALS.

高亲和力-—SPR&BLI验证

图3.Herceptin (Trastuzumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay.

申请SPR Protocol 点击咨询SPR服务

图4.Loaded Herceptin (Trastuzumab) on AHC Biosensor, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 0.825 nM as determined in BLI assay.

申请BLI Protocol 点击咨询BLI服务

图5.Erbitux (Cetuximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.3 nM as determined in a SPR assay.

申请SPR Protocol 点击咨询SPR服务

图6.Loaded Erbitux (Cetuximab) on AHC Biosensor, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.23 nM as determined in BLI assay.

申请BLI Protocol 点击咨询BLI服务

消息提示

请输入您的联系方式,再点击提交!

确定